LOS ANGELES, Jan. 13, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients ...
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...
In a comprehensive Genomic Press Interview, researchers from the University of Texas Health Science Center at San Antonio and Hirosaki University have uncovered critical new insights into the ...
The cover artistically integrates multiple elements central to investigating the developmental origins of Fragile X syndrome. A vibrant DNA double helix structure rendered in rainbow iridescent colors ...
LOS ANGELES, July 7, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients ...
Harmony Biosciences Holdings (HRMY) is in the spotlight after announcing that its Phase 3 RECONNECT study for ZYN002 in Fragile X syndrome did not meet its main goal, citing higher than expected ...
Investor's Business Daily on MSN
Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble
Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company.
To see if a treatment that targets NMDA receptors might be effective in fragile X, they tried an experimental drug called Glyx-13. This drug binds to the 2B subunit of NMDA receptors to augment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback